Key statistics
On Tuesday, Appili Therapeutics Inc (APLIF:PKC) closed at 0.021, 55.78% above the 52 week low of 0.0135 set on Oct 02, 2024.
52-week range
Open | 0.021 |
---|---|
High | 0.021 |
Low | 0.021 |
Bid | -- |
Offer | -- |
Previous close | 0.021 |
Average volume | 288.93k |
---|---|
Shares outstanding | 121.27m |
Free float | 121.19m |
P/E (TTM) | -- |
Market cap | 3.04m CAD |
EPS (TTM) | -0.0315 CAD |
Data delayed at least 15 minutes, as of Oct 08 2024 18:55 BST.
More ▼
Press releases
- Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
- Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem
- Aditxt Delivers Shareholder Update and 2024 Year-End Plan
- Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
- Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt
- Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025
- Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
- Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
- Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
- Aditxt’s Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)
More ▼